Drug Trial Radar · NCT03956355
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
May 21, 2019
Primary completion
May 26, 2020
Study completion May 26, 2020
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Biotech
- First posted
- May 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Conditions
- Plaque Psoriasis
Interventions
TapinarofDrug
Tapinarof cream, 1%, applied once daily
Vehicle CreamDrug
Vehicle cream applied once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple ImputationTime frame: Baseline to Week 12
Locations
53 sites in 2 countries. Site status is shown where the registry gives one.
Dermavant Investigative Site
Birmingham, Alabama
Dermavant Investigative Site
Phoenix, Arizona
Dermavant Investigative Site
Hot Springs, Arkansas
Dermavant Investigative Site
Rogers, Arkansas
Dermavant Investigative Site
Anaheim Hills, California
Dermavant Investigative Site
Fresno, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Northridge, California
Dermavant Investigative Site
San Diego, California
Dermavant Investigative Site
Santa Ana, California
Dermavant Investigative Site
Cromwell, Connecticut
Dermavant Investigative Site
Boca Raton, Florida
Dermavant Investigative Site
Brandon, Florida
Dermavant Investigative Site
Hialeah, Florida
Dermavant Investigative Site
Miramar, Florida
Dermavant Investigative Site
Marietta, Georgia
Dermavant Investigative Site
Evansville, Indiana
Dermavant Investigative Site
Indianapolis, Indiana
Dermavant Investigative Site
New Albany, Indiana
Dermavant Investigative Site
Louisville, Kentucky
Dermavant Investigative Site
Owensboro, Kentucky
Dermavant Investigative Site
Baton Rouge, Louisiana
Dermavant Investigative Site
New Orleans, Louisiana
Dermavant Investigative Site
New Orleans, Louisiana
Dermavant Investigative Site
Boston, Massachusetts
Dermavant Investigative Site
Clarkston, Michigan
Dermavant Investigative Site
Warren, Michigan
Dermavant Investigative Site
Saint Joseph, Missouri
Dermavant Investigative Site
Verona, New Jersey
Dermavant Investigative Site
Kew Gardens, New York
Dermavant Investigative Site
New York, New York
Dermavant Investigative Site
Rochester, New York
Dermavant Investigative Site
Cary, North Carolina
Dermavant Investigative Site
High Point, North Carolina
Dermavant Investigative Site
Norman, Oklahoma
Dermavant Investigative Site
Portland, Oregon
Dermavant Investigative Site
Pittsburgh, Pennsylvania
Dermavant Investigative Site
Johnston, Rhode Island
Dermavant Investigative Site
Arlington, Texas
Dermavant Investigative Site
College Station, Texas
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.